Risky business: target choice in adoptive cell therapy.
In this issue of Blood, Casucci et al present an elegant study that describes a potential new target for adoptive cell transfer (ACT), in this case CD44 splice variant 6 (CD44v6), and detail why it may be a good target for ACT and how to manage expected off-tumor/on-target toxicities.
NATIONAL INSTITUTES OF HEALTH.
Richard A
RA
Morgan
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology*; D016219:Immunotherapy, Adoptive; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D000951:Antigens, Neoplasm; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors